These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 23666219

  • 1. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H, Koh K, Kato M, Isobe K, Yasui N, Mori M, Akiyama K, Kikuchi A, Hanada R.
    Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL.
    Anticancer Res; 2007 Apr; 27(4C):2561-72. PubMed ID: 17695416
    [Abstract] [Full Text] [Related]

  • 3. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, Seibel NL, Dhall G.
    Cancer; 2015 Dec 01; 121(23):4205-11. PubMed ID: 26308766
    [Abstract] [Full Text] [Related]

  • 4. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP.
    Ann N Y Acad Sci; 2014 Nov 01; 1329():81-92. PubMed ID: 25098829
    [Abstract] [Full Text] [Related]

  • 5. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V, Ferster A, Uyttebroeck A, Brichard B, van der Werff Ten Bosch J, Norga K, Francotte N, Piette C, Vandemeulebroecke K, Verbeke C, Schmidt S, Benoit Y, Lammens T, De Moerloose B.
    Br J Haematol; 2020 Jul 01; 190(1):105-114. PubMed ID: 32057100
    [Abstract] [Full Text] [Related]

  • 6. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep 01; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 7. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    Gupta S, Wang C, Raetz EA, Schore R, Salzer WL, Larsen EC, Maloney KW, Mattano LA, Carroll WL, Winick NJ, Hunger SP, Loh ML, Devidas M.
    J Clin Oncol; 2020 Jun 10; 38(17):1897-1905. PubMed ID: 32275469
    [Abstract] [Full Text] [Related]

  • 8. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ.
    J Clin Oncol; 1993 Sep 10; 11(9):1780-6. PubMed ID: 8355045
    [Abstract] [Full Text] [Related]

  • 9. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
    Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ, Children's Oncology Study Group.
    J Pediatr Hematol Oncol; 2007 Sep 10; 29(9):627-32. PubMed ID: 17805038
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB, Rheingold SR, Dreyer ZE, Dahl GV, Mercedes T, Lai C, Corn T.
    Pediatr Blood Cancer; 2014 Jul 10; 61(7):1232-8. PubMed ID: 24436152
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D, Borghorst S, Lanvers-Kaminsky C, Hempel G, Gerss J, Möricke A, Schrappe M, Boos J.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):952-8. PubMed ID: 20108339
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, Hak LJ.
    Leukemia; 2003 Aug 01; 17(8):1583-8. PubMed ID: 12886246
    [Abstract] [Full Text] [Related]

  • 16. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
    Billett AL, Carls A, Gelber RD, Sallan SE.
    Cancer; 1992 Jul 01; 70(1):201-6. PubMed ID: 1606543
    [Abstract] [Full Text] [Related]

  • 17. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK, Schrøder H, Ingerslev J, Jakobsen P, Avramis VI, Müller HJ, Carlsen NT, Schmiegelow K.
    Br J Haematol; 2001 Dec 01; 115(4):983-90. PubMed ID: 11843837
    [Abstract] [Full Text] [Related]

  • 18. Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
    Schrey D, Speitel K, Lanvers-Kaminsky C, Gerss J, Möricke A, Boos J.
    Pediatr Blood Cancer; 2011 Sep 01; 57(3):378-84. PubMed ID: 21337682
    [Abstract] [Full Text] [Related]

  • 19. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE, Dreyer Z, Choi MR, Liang W, Skowronski R, Allamneni KP, Devidas M, Raetz EA, Adamson PC, Blaney SM, Loh ML, Hunger SP.
    Pediatr Blood Cancer; 2018 Mar 01; 65(3):. PubMed ID: 29090524
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.